Skip to Content
Merck
All Photos(1)

Documents

46923

Supelco

Testosterone

VETRANAL®, analytical standard

Synonym(s):

17β-Hydroxy-3-oxo-4-androstene, 17β-Hydroxy-4-androsten-3-one, 4-Androsten-17β-ol-3-one, trans-Testosterone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H28O2
CAS Number:
58-22-0
Molecular Weight:
288.42
Beilstein:
1915399
EC Number:
200-370-5
MDL number:
MFCD00003654
UNSPSC Code:
41116107
PubChem Substance ID:
329757265
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

drug control

USDEA Schedule IIIN; regulated under CDSA - not available from Sigma-Aldrich Canada

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

solubility

H2O: soluble

application(s)

forensics and toxicology
pharmaceutical (small molecule)

format

neat

SMILES string

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O

InChI

1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1

InChI key

MUMGGOZAMZWBJJ-DYKIIFRCSA-N

Gene Information

human ... AR(367)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

Testosterone secreted by the testis is converted to dihydrotestosterone in the target tissues where it appears to mediate many of the biological actions of testosterone. Androgens direct the development of the male phenotype during embryogenesis and at puberty.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Carc. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCF3787
BCBS8823V
SZBD238XV
SZBA235XV
SZBA235X

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David J Handelsman
The Journal of clinical endocrinology and metabolism, 91(5), 1646-1653 (2006-02-16)
The objective of the study was to review the rationale underlying the banning of human chorionic gonadotropin (hCG) and estrogen blockers (antiestrogens, specific estrogen receptor modulators, aromatase inhibitors) in sports for male and female athletes in the light of gender
Y Zimmerman et al.
Human reproduction update, 20(1), 76-105 (2013-10-02)
BACKGROUND; Combined oral contraceptives (COCs) reduce levels of androgen, especially testosterone (T), by inhibiting ovarian and adrenal androgen synthesis and by increasing levels of sex hormone-binding globulin (SHBG). Although this suppressive effect has been investigated by numerous studies over many
James R Bell et al.
American journal of physiology. Heart and circulatory physiology, 306(9), H1265-H1274 (2014-03-13)
Estrogen in females is conventionally considered a cardioprotective influence, but a role for estrogen in male cardioprotection has yet to be defined. Estrogen biosynthesis from testosterone is regulated by aromatase. Aromatase has recently been shown to be expressed in the
Andrea C Lo et al.
International journal of radiation oncology, biology, physics, 88(1), 87-93 (2013-12-18)
To determine (1) the prognostic utility of prostate-specific antigen (PSA) concentration at 45 to 60 months (48mPSA) after low-dose-rate prostate brachytherapy (LDR-PB); (2) the predictors of 48mPSA; and (3) the prognostic utility of directional trends between PSA levels at 24
E David Crawford et al.
Urology, 83(5), 1122-1128 (2014-03-26)
To demonstrate the safety and efficacy of up to 5 years of degarelix treatment and the effects of crossing over from leuprolide to degarelix in the extension phase of a phase III pivotal 1-year trial. Patients receiving degarelix who completed
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service